Abstract
N6-methyladenosine [m(6)A/m6A] methylation is one of the most common RNA modifications in eukaryotic cell mRNA and plays an important regulatory role in mRNA metabolism, splicing, translocation, stability, and translation. Previous studies have demonstrated that the m6A modification is highly associated with tumor cell proliferation, migration, and invasion. In the present study, five m6A regulatory factors have been revealed, namely heterogeneous nuclear ribonucleoprotein A2/B1(HNRNPA2B1), heterogeneous nuclear ribonucleoprotein C (HNRNPC), Vir like m6A methyltransferase associated protein (KIAA1429/VIRMA), RNA binding motif protein 15 (RBM15) and methyltransferase like 3 (METTL3), which are closely related to the overall survival (OS) of patients with lung adenocarcinoma (LUAD). These five m6A regulatory factors exhibited potential prognostic value for the 1, 3, and 5-years survival outcomes of LUAD patients. Our findings revealed that several signaling pathways, such as cell cycle, DNA replication, RNA degradation, RNA polymerase, nucleotide excision repair and basal transcription factors, are activated in the high-risk group of LUAD patients.
Highlights
Lung cancer is currently one of the most common malignant tumors presenting the highest fatality rate among all malignancies (Siegel et al, 2020)
The present study initially confirmed that the expression levels of five m6A regulators, including HNRNPA2B1, heterogeneous nuclear ribonucleoprotein C (HNRNPC), KIAA1429, RNA binding motif protein 15 (RBM15), and methyltransferase like 3 (METTL3) were correlated with overall survival (OS) of lung adenocarcinoma (LUAD) patients. m6A Writers regulatory factors were suggested as potential prognostic biomarkers for LUAD
The present study has discussed the m6A regulatory factorrelated genes are associated to the overall prognosis of LUAD patients, and the newly introduced prognostic model is proven to accurately prognose the outcomes of LUAD patients
Summary
Lung cancer is currently one of the most common malignant tumors presenting the highest fatality rate among all malignancies (Siegel et al, 2020). These regulators are mainly responsible for removing m6A modifications (Liu et al, 2018; Pan et al, 2018). Readers can recognize RNA methylation modifications and further regulate RNA processing, translation, and degradation (Wang et al, 2018; Ma et al, 2019). M6A Reader YTHDF2 can promote the non-small cell lung cancer (NSCLC) progression (Sheng et al, 2019), while the Eraser ALKBH5 can inhibit the metastasis of FIGURE 1 | The 16 m6A-related genes were differentially expressed in the comparison of LUAD with normal tissues. The present study initially confirmed that the expression levels of five m6A regulators, including HNRNPA2B1, HNRNPC, KIAA1429, RBM15, and METTL3 were correlated with OS of LUAD patients. The present study initially confirmed that the expression levels of five m6A regulators, including HNRNPA2B1, HNRNPC, KIAA1429, RBM15, and METTL3 were correlated with OS of LUAD patients. m6A Writers regulatory factors were suggested as potential prognostic biomarkers for LUAD
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
